TY - JOUR
T1 - International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood
T2 - Position paper by the ILAE Task Force on Nosology and Definitions
AU - Specchio, Nicola
AU - Wirrell, Elaine C.
AU - Scheffer, Ingrid E.
AU - Nabbout, Rima
AU - Riney, Kate
AU - Samia, Pauline
AU - Guerreiro, Marilisa
AU - Gwer, Sam
AU - Zuberi, Sameer M.
AU - Wilmshurst, Jo M.
AU - Yozawitz, Elissa
AU - Pressler, Ronit
AU - Hirsch, Edouard
AU - Wiebe, Sam
AU - Cross, Helen J.
AU - Perucca, Emilio
AU - Moshé, Solomon L.
AU - Tinuper, Paolo
AU - Auvin, Stéphane
N1 - Funding Information:
S.L.M. is the Charles Frost Chair in Neurosurgery and Neurology and acknowledges grant support from the National Institutes of Health (U54 NS100064 and NS43209), US Department of Defense (W81XWH‐18‐1‐0612), the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. R.P.'s research is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, Cambridge Biomedical Research Centre, the NIHR, and the Evelyn Trust. The views expressed are those of the authors and not necessarily those of funders.
Funding Information:
N.S. has served on scientific advisory boards for GW Pharma, BioMarin, Arvelle, Marinus, and Takeda; has received speaker honoraria from Eisai, BioMarin, LivaNova, and Sanofi; and has served as an investigator for Zogenix, Marinus, BioMarin, UCB, and Roche. E.C.W. has served as a paid consultant for Encoded Therapeutics and BioMarin. She is the Editor‐in‐Chief of Epilepsy.com. I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, Chiesi, Encoded Therapeutics, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, BioMarin, and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Sciences, Ovid Therapeutics, Epigenyx, Encoded Therapeutics, and Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, Care Beyond Diagnosis, Epilepsy Consortium, and UCB. R.N. has served as principal investigator in clinical trials for Novartis, Nutricia, Eisai, UCB, GW Pharma, and LivaNova. She received consulting fees from Biogene, BioMarin, GW Pharma, Zogenix, Novartis, Nutricia, Stoke, Ionis, Targeon, and Takeda and honoraria from Nutricia, Biocodex, Zogenix, GW Pharma, Advicennes, and Eisai. She has received unrestricted research grants from Eisai, UCB, LivaNova, and GW Pharma and academic research grants from EJP‐RD (horizons 2020) and IDEAL‐EPISTOP. S.M.Z. has received research support from Epilepsy Research UK, Tenovus Foundation, Glasgow Children's Hospital Charity, and Scottish Government Technology Enabled Care. He has received honoraria for educational symposia, advisory boards, and consultancy work from GW Pharma, Zogenix, Arvelle Therapeutics, and Encoded Therapeutics. J.M.W. has received paid honorarium for activities as Associate Editor of . R.P. is an investigator for studies with UCB and does consultancy work for Kephala, Ireland. She has served as a speaker and/or on advisory boards for Natus, GW, Eisai, and UCB. E.H. has received honoraria from UCB, Eisai, LivaNova, Novartis, and GW Pharmaceuticals. S.W. has received unrestricted educational grants from UCB Pharma, Eisai, and Sunovion. H.J.C. has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo, and Marinius. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her research is supported by the NIHR Biomedical Research Centre at Great Ormond Street Hospital. She holds an endowed chair at UCL Great Ormond Street Institute of Child Health; she holds grants from NIHR, EPSRC, GOSH Charity, ERUK, and the Waterloo Foundation. P.T. received speaker's or consultancy fees from Arvelle, Eisai, GW Pharma, LivaNova, UCB Pharma, Xenon Pharma, and Zogenix. S.A. has served as consultant or received honoraria for lectures from Biocodex, Biomarin, Eisai, GW Pharma, Neuraxpharm, Nutricia, UCB Pharma, Xenon, and Zogenix. He has been an investigator for clinical trials for Eisai, UCB Pharma, and Zogenix. He is an Associate Editor for . K.R. has received speaker honoraria, advisory board payments, and/or research funding from UCB, Eisai, Novartis, Zogenix, SK Lifesciences, AFT Pharmaceuticals, LivaNova, Queensland Genomic Health Alliance, Department of Health (Australia), Medicure International, Novartis, and Janssen‐Cilag. S.L.M. serves as an Associate Editor of . He is on the editorial board of , , , , and . He receives compensation from Elsevier for his work as Associate Editor of and from for his work as Associate Editor; and royalties from two books he coedited. E.P. has received speaker and/or consultancy fees from Angelini, Arvelle, Biogen, Biopas, Eisai, GW Pharma, Sanofi, SK Life Science, Takeda, UCB Pharma, Xenon Pharma, and Zogenix, and royalties from Wiley, Elsevier, and Wolters Kluwer. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Epilepsia Epilepsia Neurobiology of Disease Brain and Development Pediatric Neurology Annals of Neurology MedLink Physiological Research Neurobiology of Disease MedLink
Publisher Copyright:
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
PY - 2022/6
Y1 - 2022/6
N2 - The 2017 International League Against Epilepsy classification has defined a three-tier system with epilepsy syndrome identification at the third level. Although a syndrome cannot be determined in all children with epilepsy, identification of a specific syndrome provides guidance on management and prognosis. In this paper, we describe the childhood onset epilepsy syndromes, most of which have both mandatory seizure type(s) and interictal electroencephalographic (EEG) features. Based on the 2017 Classification of Seizures and Epilepsies, some syndrome names have been updated using terms directly describing the seizure semiology. Epilepsy syndromes beginning in childhood have been divided into three categories: (1) self-limited focal epilepsies, comprising four syndromes: self-limited epilepsy with centrotemporal spikes, self-limited epilepsy with autonomic seizures, childhood occipital visual epilepsy, and photosensitive occipital lobe epilepsy; (2) generalized epilepsies, comprising three syndromes: childhood absence epilepsy, epilepsy with myoclonic absence, and epilepsy with eyelid myoclonia; and (3) developmental and/or epileptic encephalopathies, comprising five syndromes: epilepsy with myoclonic–atonic seizures, Lennox–Gastaut syndrome, developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep, hemiconvulsion–hemiplegia–epilepsy syndrome, and febrile infection-related epilepsy syndrome. We define each, highlighting the mandatory seizure(s), EEG features, phenotypic variations, and findings from key investigations.
AB - The 2017 International League Against Epilepsy classification has defined a three-tier system with epilepsy syndrome identification at the third level. Although a syndrome cannot be determined in all children with epilepsy, identification of a specific syndrome provides guidance on management and prognosis. In this paper, we describe the childhood onset epilepsy syndromes, most of which have both mandatory seizure type(s) and interictal electroencephalographic (EEG) features. Based on the 2017 Classification of Seizures and Epilepsies, some syndrome names have been updated using terms directly describing the seizure semiology. Epilepsy syndromes beginning in childhood have been divided into three categories: (1) self-limited focal epilepsies, comprising four syndromes: self-limited epilepsy with centrotemporal spikes, self-limited epilepsy with autonomic seizures, childhood occipital visual epilepsy, and photosensitive occipital lobe epilepsy; (2) generalized epilepsies, comprising three syndromes: childhood absence epilepsy, epilepsy with myoclonic absence, and epilepsy with eyelid myoclonia; and (3) developmental and/or epileptic encephalopathies, comprising five syndromes: epilepsy with myoclonic–atonic seizures, Lennox–Gastaut syndrome, developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep, hemiconvulsion–hemiplegia–epilepsy syndrome, and febrile infection-related epilepsy syndrome. We define each, highlighting the mandatory seizure(s), EEG features, phenotypic variations, and findings from key investigations.
KW - Landau–Kleffner syndrome
KW - Lennox–Gastaut syndrome
KW - Panayiotopoulos syndrome
KW - benign occipital epilepsy
KW - childhood epilepsy with centrotemporal spikes
KW - continuous spike-and-wave in sleep
KW - eyelid myoclonia
KW - febrile infection-related epilepsy syndrome
KW - hemiconvulsion–hemiplegia–epilepsy syndrome
KW - myoclonic absences
KW - myoclonic atonic
UR - http://www.scopus.com/inward/record.url?scp=85129272393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129272393&partnerID=8YFLogxK
U2 - 10.1111/epi.17241
DO - 10.1111/epi.17241
M3 - Article
C2 - 35503717
AN - SCOPUS:85129272393
SN - 0013-9580
VL - 63
SP - 1398
EP - 1442
JO - Epilepsia
JF - Epilepsia
IS - 6
ER -